PMID- 29660177
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20220114
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 101
IP  - 1
DP  - 2018 Jul
TI  - Severe adverse events by tyrosine kinase inhibitors decrease survival rates in 
      patients with newly diagnosed chronic-phase chronic myeloid leukemia.
PG  - 95-105
LID - 10.1111/ejh.13081 [doi]
AB  - OBJECTIVE: This multicenter cooperative study aimed to analyze the adverse events 
      (AEs) associated with tyrosine kinase inhibitors (TKIs) used as initial treatment 
      for chronic-phase chronic myeloid leukemia (CML-CP) and their impact on outcome. 
      METHODS: We retrospectively evaluated 450 patients with CML-CP who received TKIs 
      between 2004 and 2014. RESULTS: The 5-year overall survival (OS) and event-free 
      survival (EFS) rates were 95.1% and 89.0%, respectively. Patients with 
      comorbidities (46.4%) and aged >/=60 years (50.4%) at diagnosis had significantly 
      inferior OS to those without comorbidities and aged <60. Patients achieved higher 
      rates of major molecular response (MMR) at 6 and 12 months after initial 
      treatment with dasatinib or nilotinib compared to imatinib, but final MMR rates 
      were almost the same. Sixty-six percent of patients required treatment 
      modifications from first-line TKI therapy; the main reasons were AEs (48.4%) and 
      failure (18%). Grade III-IV AEs in first-line TKI therapy were significantly 
      correlated to inferior OS/EFS compared to grade 0-II AEs. CONCLUSION: Although 
      long-term outcomes were similar in CML-CP patients treated with each TKI 
      regardless of first-line TKI selection, severe AEs in first-line TKI therapy 
      decreased their survival rates. Early change in TKIs is recommended, when faced 
      with severe AEs of specific TKIs.
CI  - (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Ota, Shuichi
AU  - Ota S
AUID- ORCID: 0000-0002-3631-244X
AD  - Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
FAU - Matsukawa, Toshihiro
AU  - Matsukawa T
AD  - Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan.
FAU - Yamamoto, Satoshi
AU  - Yamamoto S
AD  - Department of Hematology, Sapporo City General Hospital, Sapporo, Japan.
FAU - Ito, Shinichi
AU  - Ito S
AD  - Department of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
FAU - Shindo, Motohiro
AU  - Shindo M
AD  - Department of Hematology, Asahikawa Medical University, Asahikawa, Japan.
FAU - Sato, Kazuya
AU  - Sato K
AD  - Department of Hematology/Oncology, Asahikawa Kosei Hospital, Asahikawa, Japan.
FAU - Kondo, Takeshi
AU  - Kondo T
AD  - Faculty of Medicine and Graduate School of Medicine, Department of Hematology, 
      Hokkaido University, Sapporo, Japan.
FAU - Kohda, Kyuhei
AU  - Kohda K
AD  - Department of Hematology, Japanese Red Cross Asahikawa Hospital, Asahikawa, 
      Japan.
FAU - Sakai, Hajime
AU  - Sakai H
AD  - Department of Hematology, Teine Keijinkai Hospital, Sapporo, Japan.
FAU - Mori, Akio
AU  - Mori A
AD  - Department of Hematology, Aiiku Hospital, Sapporo, Japan.
FAU - Takahashi, Tohru
AU  - Takahashi T
AD  - Department of Hematology, Tenshi Hospital, Sapporo, Japan.
FAU - Ikeda, Hiroshi
AU  - Ikeda H
AD  - Department of Hematology, Sapporo Medical University, Sapporo, Japan.
FAU - Kuroda, Hiroyuki
AU  - Kuroda H
AD  - Department of Hematology, Steel Memorial Muroran Hospital, Muroran, Japan.
FAU - Haseyama, Yoshihito
AU  - Haseyama Y
AD  - Department of Hematology, Tonan Hospital, Sapporo, Japan.
FAU - Yamamoto, Masaki
AU  - Yamamoto M
AD  - Department of Pediatrics, Sapporo Medical University, Sapporo, Japan.
FAU - Sarashina, Takeo
AU  - Sarashina T
AD  - Department of Pediatrics, Asahikawa Medical University, Asahikawa, Japan.
FAU - Yoshida, Makoto
AU  - Yoshida M
AD  - Department of Pediatrics, Japanese Red Cross Asahikawa Hospital, Asahikawa, 
      Japan.
FAU - Kobayashi, Ryoji
AU  - Kobayashi R
AD  - Department of Hematology/Oncology for Children and Adolescent, Sapporo Hokuyu 
      Hospital, Sapporo, Japan.
FAU - Nishio, Mitsufumi
AU  - Nishio M
AD  - Department of Hematology and Oncology, NTT East Japan Sapporo Hospital, Sapporo, 
      Japan.
FAU - Ishihara, Toshimichi
AU  - Ishihara T
AD  - Department of Hematology, Kin-ikyo Chuo Hospital, Sapporo, Japan.
FAU - Hirayama, Yasuo
AU  - Hirayama Y
AD  - Department of Hematology, Higashisapporo Hospital, Sapporo, Japan.
FAU - Kakinoki, Yasutaka
AU  - Kakinoki Y
AD  - Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan.
FAU - Kobayashi, Hajime
AU  - Kobayashi H
AD  - Department of Hematology, Obihiro Kosei Hospital, Obihiro, Japan.
FAU - Fukuhara, Takashi
AU  - Fukuhara T
AD  - Palliative Care Center, Sapporo Kosei Hospital, Sapporo, Japan.
FAU - Imamura, Masahiro
AU  - Imamura M
AD  - Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
FAU - Kurosawa, Mitsutoshi
AU  - Kurosawa M
AD  - Department of Hematology, Hokkaido Cancer Center, Sapporo, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180523
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - F41401512X (nilotinib)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Dasatinib/administration & dosage/adverse effects
MH  - Female
MH  - Fusion Proteins, bcr-abl/*antagonists & inhibitors/genetics/metabolism
MH  - *Gene Expression Regulation, Leukemic
MH  - Humans
MH  - Imatinib Mesylate/administration & dosage/adverse effects
MH  - Leukemia, Myeloid, Chronic-Phase/*diagnosis/drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/administration & dosage/*adverse effects
MH  - Pyrimidines/administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adverse events
OT  - chronic myeloid leukemia
OT  - dasatinib
OT  - imatinib
OT  - nilotinib
OT  - tyrosine kinase inhibitor
EDAT- 2018/04/17 06:00
MHDA- 2018/10/12 06:00
CRDT- 2018/04/17 06:00
PHST- 2018/04/04 00:00 [accepted]
PHST- 2018/04/17 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2018/04/17 06:00 [entrez]
AID - 10.1111/ejh.13081 [doi]
PST - ppublish
SO  - Eur J Haematol. 2018 Jul;101(1):95-105. doi: 10.1111/ejh.13081. Epub 2018 May 23.